Podocyte Adaptation Proliferation and Ageing

Informazioni relative al progetto

PAPAstudy

ID dell’accordo di sovvenzione: 679254

DOI

10.3030/679254

Progetto chiuso

Data della firma CE 19 Febbraio 2016

Data di avvio 1 Marzo 2016

Data di completamento 28 Febbraio 2021

Finanziato da

• EXCELLENT SCIENCE - European Research Council (ERC)

Costo totale

€ 1 479 260,00

Contributo UE

€ 1 479 260,00

Coordinato da

UNIVERSITE PARIS CITE
France

Periodic Reporting for period 4 - PAPAstudy (Podocyte Adaptation Proliferation and Ageing)

Periodo di rendicontazione: 2020-09-01 al 2021-02-28

Sintesi del contesto e degli obiettivi generali del progetto

The PAPAstudy project aims at discovering new treatment for rare disorders involving the PIK3CA/AKT/mTOR pathway. Our goal is to offer to patients molecular targeted therapy. To this aim we are using complementary in vivo and in vitro approaches, innovative new technology of bioengineering and we develop genetically modified mouse models. We are located in the close vicinity of the clinical department allowing bed to beachside or vice et versa approaches.

This project has broken all the boundaries that were existing between different medical specialities and allowed the
rapid repurposing of a new drug undergoing development in oncology. This project is clearly considered by outside experts as a breakthrough discovery.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Since the beginning of the project, we did develop a new way to isolate primary podocytes (our cells of interest) from mice and to grow them up in vitro. The podocyte is a highly specialized cell with foot processes expansion that function as vasculature-supporting cells, producing basement membrane components and a number of vascular growth factors. These cells play an essential role in renal physiology but their unique localization, as the primary filter, exposes them to many stresses in pathological conditions. In fact these cells are the direct target of many diseases such as diabetes or HIV. We are currently testing and developing various mouse models.

The project resulted in a patent application that has been filled in by the Université de Paris.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Using this method, we discovered promising treatment for other disorders such as mitochondrial diseases, antiphospholipid vasculopathy, CLOVES syndrome or other PIK3CA related overgrowth syndrome.

gcanaud.jpg